Clinical Trial Detail

NCT ID NCT03117309
Title Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Michael B. Atkins, MD
Indications

renal cell carcinoma

Therapies

Ipilimumab + Nivolumab

Nivolumab

Age Groups: senior adult

No variant requirements are available.